Preclinical Animal Models of MASLD and MASH: A Review of disease induction strategies

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major worldwide health concern, covering a wide range of conditions from basic hepatic steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advancing fibrosis, cirrhosis, and hepatocellular carcinoma. Growing disease burden alongside the scarcity of effective treatment options underscores the urgent need for dependable preclinical models are faithfully mimic the intricate metabolic and pathological aspects of a human condition. This review offers a thorough examination of animal models employed to study MASLD and MASH, focusing especially on their disease induction methods, pathological traits, metabolic characteristics, time required for disease development, and relevance to human translation. Dietary models such as High-fat diet, High-fat high-fructose diet, High-fat high-cholesterol diet, methionine and choline-deficient diet, choline-deficient L-amino acid defined diet, GAN diet, and ALIOS models recapitulate various stages of metabolic dysfunction and liver damage. Chemical models including streptozotocin, carbon tetrachloride, diethylnitrosamine, and thioacetamide prove valuable for hastening fibrosis and hepatocarcinogenesis. Genetically modified models like ob/ob, db/db, foz/foz, B6-Alms1-del, Ldlr−/−, and Apoe−/− mice shed light on the genetic and metabolic factors driving disease progression. Combination models merge dietary, chemical, and genetic strategies to more accurately reproduce advanced MASH and fibrosis. Emerging infection- and immunity-induced models further broaden opportunities to explore specific disease mechanisms. Overall, no single model completely mirrors human MASLD and MASH; thus, model selection ought to be directed by the particular research goal and disease stage being studied.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24413494
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preclinical Animal Models of MASLD and MASH: A Review of disease induction strategies

Venu Talla, Kompelli Bhanudeepika, Bathula Jayasri
Zenodo (CERN European Organization for Nuclear Research)
Liver Disease Diagnosis and Treatment
article

Preclinical Animal Models of MASLD and MASH: A Review of disease induction strategies

Venu Talla, Kompelli Bhanudeepika, Bathula Jayasri
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major worldwide health concern, covering a wide range of conditions from basic hepatic steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advancing fibrosis, cirrhosis, and hepatocellular carcinoma. Growing disease burden alongside the scarcity of effective treatment options underscores the urgent need for dependable preclinical models are faithfully mimic the intricate metabolic and pathological aspects of a human condition. This review offers a thorough examination of animal models employed to study MASLD and MASH, focusing especially on their disease induction methods, pathological traits, metabolic characteristics, time required for disease development, and relevance to human translation. Dietary models such as High-fat diet, High-fat high-fructose diet, High-fat high-cholesterol diet, methionine and choline-deficient diet, choline-deficient L-amino acid defined diet, GAN diet, and ALIOS models recapitulate various stages of metabolic dysfunction and liver damage. Chemical models including streptozotocin, carbon tetrachloride, diethylnitrosamine, and thioacetamide prove valuable for hastening fibrosis and hepatocarcinogenesis. Genetically modified models like ob/ob, db/db, foz/foz, B6-Alms1-del, Ldlr−/−, and Apoe−/− mice shed light on the genetic and metabolic factors driving disease progression. Combination models merge dietary, chemical, and genetic strategies to more accurately reproduce advanced MASH and fibrosis. Emerging infection- and immunity-induced models further broaden opportunities to explore specific disease mechanisms. Overall, no single model completely mirrors human MASLD and MASH; thus, model selection ought to be directed by the particular research goal and disease stage being studied.

Zenodo (CERN European Organization for Nuclear Research)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Preclinical Animal Models of MASLD and MASH: A Review of disease induction strategies — Venu Talla, Kompelli Bhanudeepika, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS